Updating results

Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: TBC

Technology appraisal guidance In development

IMCgp100 for treating metastatic uveal melanoma (ID1441)

In development [GID-TA10428] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

In development [GID-TA10474] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

In development [GID-TA10473] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

In development [GID-TA10223] Expected publication date: TBC

Technology appraisal guidance In development

Eculizumab for treating refractory myasthenia gravis [ID1064]

In development [GID-TA10176] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Technology appraisal guidance In development

Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Technology appraisal guidance In development

Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Technology appraisal guidance In development

Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

In development [GID-TA10494] Expected publication date: TBC

Technology appraisal guidance In development

Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: TBC

Technology appraisal guidance In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 10 November 2020

Antimicrobial prescribing guideline In development

Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

In development [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

In development [GID-TA10546] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

In development [GID-TA10221] Expected publication date: TBC

Technology appraisal guidance In development

Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 21 October 2020

NICE guideline In development

Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

Managing common infections - antimicrobial prescribing guidelines

In development [GID-NG10050] Expected publication date: TBC

NICE guideline In development

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

In development [GID-NG10161] Expected publication date: TBC

NICE guideline In development

Type 1 diabetes in adults: diagnosis and management (update)

In development [GID-NG10159] Expected publication date: TBC

NICE guideline In development

Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

NICE guideline In development

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: 07 April 2021

NICE guideline In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis - diacerein [ID332]

In development [GID-TAG250] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Technology appraisal guidance In development

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Technology appraisal guidance In development

Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Technology appraisal guidance In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development